MNMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.485

+18.18%

-0.453

+29.52%

-0.452

-9.67%

Estimates Revision

Stock Price

Go Up

+17.19%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 28.25 USD with a low forecast of 18.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

18.00

Averages

28.25

High

55.00

Current: 0.000

Low

18.00

Averages

28.25

High

55.00

Needham

Buy

maintain

$28

2026-01-05

New

Reason

Needham

Price Target

$28

2026-01-05

New

maintain

Buy

Reason

Needham named Mind Medicine a top pick for 2026 and added the stock to its Conviction List. The firm keeps a Buy rating on the shares with a $28 price target. Mind has a "catalyst-rich" 2026 with three pivotal readouts, the analyst tells investors in a research note. Needham sees the readouts making 2026 a "transformative year" for the company. Mind's MM120 is "de-risked" in generalized anxiety disorder based on the "robust" Phase 2b data, the firm contends.

JonesResearch

NULL -> Buy

initiated

$61

2025-12-23

Reason

JonesResearch

Price Target

$61

2025-12-23

initiated

NULL -> Buy

Reason

JonesResearch initiated coverage of Mind Medicine with a Buy rating and $61 price target. The firm, which anticipates that "strong" clinical data from earlier stages will translate into positive Phase 3 results for lead asset MM120 in generalized anxiety disorder and major depressive disorder, views MindMed as poised to take advantage of current trends favoring the development of psychedelic agents in psychiatry, the analyst tells investors.

Canaccord

Buy

upgrade

$16 -> $25

2025-11-07

Reason

Canaccord

Price Target

$16 -> $25

2025-11-07

upgrade

Buy

Reason

Canaccord raised the firm's price target on Mind Medicine to $25 from $16 and keeps a Buy rating on the shares. The firm added its MDD drug potential to its model and said the company is well capitalized and significantly undervalued heading into Phase 3 data.

LifeSci Capital

Francois Brisebois

Outperform

initiated

$32

2025-10-14

Reason

LifeSci Capital

Francois Brisebois

Price Target

$32

2025-10-14

initiated

Outperform

Reason

LifeSci Capital analyst Francois Brisebois initiated coverage of Mind Medicine with an Outperform rating and $32 price target.

Oppenheimer

Jay Olson

Outperform

initiated

$25

2025-08-04

Reason

Oppenheimer

Jay Olson

Price Target

$25

2025-08-04

initiated

Outperform

Reason

Oppenheimer analyst Jay Olson resumed coverage of Mind Medicine with an Outperform rating and $25 price target. The firm previously had no rating on the shares. The analyst has "high conviction" that the company's lead asset MM120 will "revolutionize" neuropsychiatry with its potential to drive durable remission. MM120 has a "unique" clinical profile with its less-intense but longer psychedelic experience compared to other approaches, the analyst tells investors in a research note.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$55

2025-03-07

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$55

2025-03-07

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Mind Medicine (MindMed) Inc (MNMD.O) is -7.41, compared to its 5-year average forward P/E of -6.32. For a more detailed relative valuation and DCF analysis to assess Mind Medicine (MindMed) Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.32

Current PE

-7.41

Overvalued PE

-1.10

Undervalued PE

-11.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.23

Current EV/EBITDA

-5.92

Overvalued EV/EBITDA

8.11

Undervalued EV/EBITDA

-28.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MNMD News & Events

Events Timeline

No data

News

6.0

2025-12-23SeekingAlpha

Jones Initiates Coverage on MindMed, Highlighting Potential of Psychedelics for Mental Health Treatment

8.0

2025-12-19SeekingAlpha

Psychedelic Stocks May Gain from Marijuana Rescheduling, According to Jefferies

1.0

2025-12-18Businesswire

MindMed CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026

People Also Watch

Frequently Asked Questions

What is Mind Medicine (MindMed) Inc (MNMD) stock price today?

The current price of MNMD is 13.84 USD — it has decreased -5.85 % in the last trading day.

What is Mind Medicine (MindMed) Inc (MNMD)'s business?

Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

What is the price predicton of MNMD Stock?

What is Mind Medicine (MindMed) Inc (MNMD)'s revenue for the last quarter?

Mind Medicine (MindMed) Inc revenue for the last quarter amounts to -45.67M USD, increased 84.21 % YoY.

What is Mind Medicine (MindMed) Inc (MNMD)'s earnings per share (EPS) for the last quarter?

Mind Medicine (MindMed) Inc. EPS for the last quarter amounts to -29567000.00 USD, decreased % YoY.

What changes have occurred in the market's expectations for Mind Medicine (MindMed) Inc (MNMD)'s fundamentals?

The market is revising No Change the revenue expectations for MNMD for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 17.19%.

How many employees does Mind Medicine (MindMed) Inc (MNMD). have?

Mind Medicine (MindMed) Inc (MNMD) has 74 emplpoyees as of January 10 2026.

What is Mind Medicine (MindMed) Inc (MNMD) market cap?

Today MNMD has the market capitalization of 1.36B USD.